Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Why the future of marijuana legalization remains hazy despite high public support 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
The four types of dementia most people don’t know exist 
CDC Monitors U.S. Travelers After Hantavirus Outbreak on Luxury Cruise Ship 
Supreme Court Blocks 5th Circuit Ruling on Abortion Pill Access 
OpenAI May Delay IPO to 2027 Amid $1 Trillion Valuation Goal 
Johns Hopkins University Lays Off 110 Employees as Federal Research Funding Declines 
Bayer Wins Major U.S. Supreme Court Roundup Lawsuit, Shares Surge 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Italy Investigates Microsoft Over Microsoft 365 AI Subscription Price Hike 
RFK Jr. Faces Scrutiny Over David Geier’s HHS Role and Vaccine Review Work 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
British pharmaceutical giant GSK plc (LON:GSK) is reportedly in advanced negotiations to acquire U.S.-based cancer drug developer Nuvalent Inc. (NASDAQ: NUVL) in a deal that could be worth more than $9 billion, according to a report published by the Financial Times on Tuesday.
Sources familiar with the matter said both companies are working toward finalizing an agreement as early as this week. However, discussions remain ongoing, and there is still a possibility that the deal could fall through if last-minute challenges arise.
If completed, the proposed acquisition would value Massachusetts-headquartered Nuvalent between $9 billion and $10 billion. The valuation represents a substantial premium over Nuvalent’s market capitalization, which stood at nearly $7 billion at the close of trading on Monday.
The potential takeover would mark GSK’s largest acquisition in more than a decade and rank among the most significant transactions in the company’s history. The move aligns with CEO Luke Miels’ strategy to expand and strengthen GSK’s oncology portfolio as the pharmaceutical industry increasingly focuses on innovative cancer treatments.
Nuvalent has gained attention for its work in developing targeted cancer therapies designed to address resistance mechanisms in tumors. Its lead drug candidate, neladalkib, is being developed for the treatment of lung cancer and is currently under review by U.S. regulators. Approval of the therapy could significantly enhance Nuvalent’s value and commercial prospects.
The reported deal comes during a period of heightened activity in the global biotechnology sector. According to Dealogic data cited in the report, biotech and pharmaceutical mergers and acquisitions have reached nearly $211 billion in announced transactions so far this year, highlighting strong demand for promising drug-development companies.
Should the acquisition move forward, it would further reinforce GSK’s commitment to cancer research and provide the company with valuable assets in the rapidly growing oncology market.
